Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 237 publications.
Skip to main content
Nahas SJ, Zhao Y, Graham CN, Erbe A, Blumenfeld A. Comparative efficacy of AXS-07 vs. gepants for acute treatment of migraine: a network meta-analysis. Poster presented at the American Academy of Neurology (AAN) 2025 Annual Meeting; April 2025.
Ailawadhi S, Inocencio TJ, Mansfield C, Chintakayala P, Bussberg C, Chi L, Harnett J, Kroog GS, Rodriguez-Lorenc K, Ma Q. Patient preferences for triple-class–exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study. Future Oncol. 2025 Mar;21(7):853-65. doi: 10.1080/14796694.2025.2461430
Blauvelt A, Reckleff J, Zhao Y, Clark M, Kosa K, Harris N, Esfandiari E, Martin S, Whalley D, Emma GY. Content evaluation of pruritus, skin pain, and sleep disturbance patient-reported outcome measures in adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. Br J Dermatol. 2025 Jan 24;192(2):247-60. doi: 10.1093/bjd/ljae346
Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial. Cancer. 2024 Oct 15;130(20):3426-35. doi: 10.1002/cncr.35438
Blauvelt A, Reckleff J, Zhao Y, Clark M, Kosa K, Harris N, Esfandiari E, Martin S, Whalley D, Emma GY. Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. Br J Dermatol. 2024 Oct 4. doi: 10.1093/bjd/ljae346
Herring WL, Wittrup-Jensen V, Fox L. Value assessment of emerging treatments for nonalcoholic steatohepatitis: lessons from Institute for Clinical and Economic Review evaluations. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S76. doi: 10.1016/j.jval.2024.03.403
Brehler R, Melen E, Janson C, Abeysinghe S, Njue A, Marcano Belisario J. Systematic literature review and adjusted indirect treatment comparisons of 2 allergen immunotherapy treatments for grass pollen-induced allergic rhinitis. Poster presented at the EAACI Congress 2024; May 31, 2024. Valencia, Spain.
Golan Y, Amin A, Dubberke E, Wilson M, Nguyen D, Kvasz M. Budget impact analysis of VOWST™ oral spores (VOS, formerly SER-109) for prevention of recurrent clostridioides difficile infection (CDI) in the United States. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 2024; April 15, 2024. New Orleans, LA. [abstract] J Manag Care Spec Pharm. 2024 Apr; 30(4-2):S8.
Brown TM, Vera-Llonch M, Kanu C, Sikora Kessler A, Yarlas A, Fehnel SE. Cross-sectional quantitative evaluation of a novel patient-reported outcome measure in familial chylomicronemia syndrome. Patient Relat Outcome Meas. 2024 Feb 15;15:45-59. doi: 10.2147/PROM.S441583
Callahan LF, Samsell B, DiBenedetti D, Frangiosa T, Slota C, Biggar V, Paulsen R, Lappin D, Herring WL, Romano (DeMuro) C. Evaluating elements of the care partner experience in individuals who care for people with Alzheimer's disease across the severity spectrum. Neurol Ther. 2024 Feb;13(1):53-67. doi: 10.1007/s40120-023-00558-6
DiBenedetti D, Kosa K, Waters HC, Oberdhan D. Understanding patients' experiences with borderline personality disorder: qualitative interviews. Neuropsychiatr Dis Treat. 2023 Oct 9;19:2115-25. doi: 10.2147/NDT.S423882
DiBenedetti D, Huang M-Y, Kosa K, Suthoff E, Bonthapally V, Lasser R, Pollack M, Doherty J, Mak C, Cutler AJ, Mattingly GW. Assessing individuals' experiences with zuranolone for major depressive disorder: qualitative interviews with participants from the open-label shoreline study. Poster presented at the 2023 ASCP Annual Meeting; May 31, 2023. Miami Beach, FL.
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Katzmann JL, Laufs U, Diamand F, Wolowacz S, Becker C, Bilitou A. Addition of bempedoic acid to the lipid-lowering treatment pathway for high and very high-risk patients in Germany: a simulation study using the SANTORINI observational study cohort. Poster presented at the DGK 89th Annual Meeting; April 13, 2023. Mannheim, Germany.
Lansdall CJ, McDougall F, Butler LM, Delmar P, Pross N, Qin S, McLeod L, Zhou X, Kerchner GA, Doody RS. Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease. J Prev Alzheimers Dis. 2023;10(1):9-18. doi: 10.14283/jpad.2022.102
Copley-Merriman C, D'Souza V, Arvin-Berod C, Phillips G, Verheesen P, Heyerick A, Stoykov I. Evidence gap analysis of the burden of illness and treatment of pemphigus vulgaris and foliaceus. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S41. doi: 10.1016/j.jval.2022.09.198
Yang J, Masaquel C, Arvin-Berod C, Phillips G, Godar M, Desai M, Ayguasanosa J. Evidence gap analysis of the burden of illness and treatment of primary immune thrombocytopenia. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S19. doi: 10.1016/j.jval.2022.09.094
Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Published Erratum - Correction to: Staging disease severity using the Alzheimer's Disease Composite Score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Jun;11(2):915-27. doi: 10.1007/s40120-022-00340-0
Chebib FT, Zhou X, Garbinsky D, Davenport E, Sasikiran N, Oberdhan O, Fernandes A. Pooled data analysis of the long-term effect of Tolvaptan in patients between 56 and 65 years with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Poster presented at the National Kidney Foundation Spring Clinical Meetings; April 6, 2022. Boston, MA.
Stander S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, Williams N, Sciascia T, Augustin M. Worst itch numerical rating scale for Prurigo Nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):573-81. doi: 10.1111/jdv.17870
Gnanasakthy A, Norcross L, (Demuro) Romano C, Carson RT. A review of patient-reported outcome labeling of FDA-approved new drugs (2016-2020): counts, categories, and comprehensibility. Value Health. 2022 Apr;25(4):647-55. doi: 10.1016/j.jval.2021.10.006
Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Staging disease severity using the Alzheimer's disease composite score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Mar;11(1):413-34. doi: 10.1007/s40120-022-00326-y
Mordin M, Parrish W, Masaquel C, Bisson B, Copley-Merriman K. Intra-articular hyaluronic acid for osteoarthritis of the knee in the United States: a systematic review of economic evaluations. Clin Med Insights Arthritis Musculoskelet Disord. 2021 Nov 19;14:1-13. doi: 10.1177/11795441211047284
DuBrock HM, Nathan SD, Reeve BB, Kolaitis NA, Mathai SC, Classi PM, Nelsen AC, Olayinka-Amao B, Norcross LN, Martin SA. Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life. Pulm Circ. 2021 Apr 1;11(2):204589402. doi: 10.1177/20458940211005641
Winnette R, Martin S, Harris N, Deal LS. Development of the alopecia areata patient priority outcomes instrument: a qualitative study. Dermatol Ther. 2021 Apr;11(2):599-613. doi: 10.1007/s13555-021-00508-w
Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tanko LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano (DeMuro) C, Williams VSL, Vissing J, Auberson LZ, RESILIENT Study Extension Group . Efficacy and safety of Bimagrumab in sporadic inclusion body Myositis: long-term extension of RESILIENT. Neurology. 2021 Mar 23;96(12):e1595-607. doi: 10.1212/WNL.0000000000011626
Popat S, Tanna N, Hartridge-Lambert S, Kiff C, Sowdani A, Rothwell B, Brodtkorb T-H, Ling C, Smittenaar R, Bomb M, Turnbull A. Nivolumab in second line non-small cell lung cancer – comparing real-world outcomes in England to CheckMate (CM) 017 and 057. Poster presented at the IASLC 2020 Virtual World Conference on Lung Cancer; January 28, 2021.
Mamolo C, Welch V, Walter RB, Cappelleri JC, Brockbank J, Cawson M, Knight C, Wilson M. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. Pharmacoeconomics. 2021 Jan;39(1):121-31. doi: 10.1007/s40273-020-00976-6
Purser M, Gallagher M, Mladsi D, Weber JM, Andemariam B, Kaye JA, Chawla A. Evaluation of published models in sickle cell disease against key criteria for an economic model for a potentially curative one-time treatment. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2). doi: 10.1016/j.jval.2020.08.098
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Davidson D, Stevenson M, Llonch MV, Hsieh A, Brown TM, Slota C, Fehnel S. Development of a novel patient-reported outcome measure symptoms and impacts of familial chylomicronemia syndrome. J Clin Lipidol. 2020 Jul;14(4):P571.
Sierra J, Mareque M, Montesinos P, Guinea JM, Font P, Oyaguez I, Brockbank J, Candini D, Llinares J, Soto J, De La Fuente A. Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy for first-line treatment of patients with CD33-positive acute myeloid leukemia in Spain. Poster presented at the 2020 Virtual European Hematology Association; June 2020.
Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos MA. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial. Eur J Haematol. 2020 May;104(5):443-58. doi: 10.1111/ejh.13379.
Filonenko A, Purser M, Mader G, Graham J. Impact of increased utilization of long-acting reversable contraceptive methods among young women on cost and unintended pregnancies (UP) in the United States (US). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S153. doi: 10.1016/j.jval.2020.04.371
Aggarwal K, Vredenburg M, Mladsi D, Barnett C. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 2020 AMCP Meeting (Conference cancelled); April 2020. [abstract] J Manag Care Pharm. 2020 Apr; 26(Supplement 4a):s58.
Mladsi D, Hess LM, Barnett CL, Njue A, Huang YJ, Cui ZL, Bowman L. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study. J Med Econ. 2020 Mar;23(3):213-20. doi: 10.1080/13696998.2019.1678479
Purser M, Gallagher M, Mladsi D, Weber JM, Andermariam B, Kaye JA, Chawla A. Development of key criteria for an economic model for a potentially curative one-time treatment for sickle cell disease and evaluation of published models with respect to these criteria. Hemasphere. 2020;p.1098-9.
Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Stull K, Esterberg E, Ajmera M, Candrilli S, Kitt TM, Spalding JR, Patel VP. Use of antifungals and outcomes among inpatients at risk of invasive aspergillosis or mucormycosis in the USA: a retrospective cohort study. Infect Dis Ther. 2019 Dec;8(4):641-55. doi: 10.1007/s40121-019-00267-4
Allen LF, Aggarwal K, Vredenburg M, Barnett C, Mladsi D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 61st ASH American Society of Hematology Annual Meeting and Exposition; December 8, 2019. San Diego, CA. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):3454. doi: 10.1182/blood-2019-131822
Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019 Oct;12(5):445-9. doi: 10.1007/s40271-019-00373-y
Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Odom D, Gnanasakthy A, Suryanarayan K, Cain L, Romanus D, Rajkumar SV, Dimopoulos MA. Health-related quality of life (HRQOL) outcomes of oral ixazombi maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed mulitple myeloma (NDMM) from TOURMALINE-MM3. Poster presented at the 24th Congress of the European Hematology Association; June 2019. Amsterdam, The Netherlands. [abstract] Hemasphere. 2019 Jun; 3:266-7.
Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb TH, Mendelsohn AB, Lowry S, Wu JJ, Feldman SR, Armstrong AW. Budget-impact and cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis from a US health plan perspective. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.
Lewis EF, Coles TM, Lewis S, Nelson LM, Barrett A, DeMuro Romano C, Stull DE, Turner SJ, Chang CG. Development, psychometric evaluation, and initial feasibility assessment of a symptom tracker for use by patients with heart failure (HFaST). J Patient Rep Outcomes. 2019 May 2;3(1):26. doi: 10.1186/s41687-019-0113-6
Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness of tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis. Poster presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting; March 1, 2019. Washington, DC. Previously presented at the 2018 Academy of Managed Care Pharmacy (AMCP) Nexus Conference.
Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis. Poster presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting; March 1, 2019. Washington, DC. Previously presented at the 2018 Academy of Managed Care Pharmacy (AMCP) Nexus Conference.
Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul;24(7):617-22. doi: 10.18553/jmcp.2018.24.7.617
Saltus CW, Calingaert B, Candrilli S, Lorenzo M, D’yachkova Y, Otto T, Wagner U, Kaye JA. Epidemiology of adult soft-tissue sarcomas in Germany. Sarcoma. 2018 Apr 4;2018:5671926. doi: 10.1155/2018/5671926